肺高血压的移植、桥接与支持技术
尽管肺高血压(PH)药物治疗已有进展,部分患者仍会出现适应不良性右心室表型。终末期PH管理需多学科协作并早期识别易急性失代偿者,移植候选评估应早期进行,双肺移植是首选但需专家围术期管理以降低肺水肿和原发性移植物功能障碍风险。右心室辅助技术进展和移植物分配方案调整改善了危重患者ICU生存,使其能等待紧急移植,专科中心对优化结局不可或缺。
要点
- 终末期PH需多学科管理并早期识别易急性失代偿患者
- 移植候选评估与可行性判断应早期纳入治疗流程
- 双肺移植是首选但需专家围术期管理以降低并发症风险
核心结论
- 尽管PH药物治疗有进展,部分患者仍出现适应不良性右心室表型,终末期管理需多学科协作和早期识别易急性失代偿者。
- 移植候选评估应早期进行,纳入移植名单需综合风险评估并考虑PH类型和影响等待时间的因素。
- 双肺移植是首选但需专家围术期管理以降低PH患者肺水肿和原发性移植物功能障碍风险。
- 右心室辅助技术进展和移植物分配方案调整改善了危重患者ICU生存,使其能等待紧急移植。
- 能提供综合照护的专科中心对优化PH患者结局不可或缺。
研究设计与样本
- 本文为Eur Respir J发表的综述,围绕肺高血压的移植、桥接与支持技术进行论述,未报告系统检索范围。
主要发现
- 部分PH患者虽经药物治疗仍出现适应不良性右心室表型。
- 终末期PH管理面临重大挑战,需多学科方法和早期识别易急性失代偿患者。
- 急性PH失代偿事件可能不可预测,即使优化内科治疗仍可导致难治性右心室衰竭,需救援治疗。
- 右心室辅助技术进展和移植物分配方案调整显著改善了危重患者ICU生存。
临床怎么用
- 应在治疗流程早期识别潜在移植候选者并评估移植可行性。
- 纳入移植名单需综合风险评估,并考虑PH具体类型和影响等待时间的因素。
- 双肺移植患者需专家围术期和术后管理以降低肺水肿和原发性移植物功能障碍风险。
- 对优化内科治疗仍发生难治性右心室衰竭的急性失代偿患者需使用救援治疗。
- 危重患者可借助右心室辅助技术和调整后的移植物分配方案在ICU维持生存以等待紧急移植。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the progress made in medical therapies for treating pulmonary hypertension (PH), a subset of patients remain susceptible to developing a maladaptive right ventricular phenotype. The effective management of end-stage PH presents substantial challenges, necessitating a multidisciplinary approach and early identification of patients prone to acute decompensation. Identifying potential transplant candidates and assessing the feasibility of such a procedure are pivotal tasks that should be undertaken early in the treatment algorithm. Inclusion on the transplant list is contingent upon a comprehensive risk assessment, also considering the specific type of PH and various factors affecting waiting times, all of which should inform the decision-making process. While bilateral lung transplantation is the preferred option, it demands expert intra- and post-operative management to mitigate the heightened risks of pulmonary oedema and primary graft dysfunction in PH patients. Despite the availability of risk assessment tools, the occurrence of acute PH decompensation episodes can be unpredictable, potentially leading to refractory right ventricular failure even with optimal medical intervention, necessitating the use of rescue therapies. Advancements in right ventricular assist techniques and adjustments to graft allocation protocols for the most critically ill patients have significantly enhanced the survival in intensive care, affording the opportunity to endure while awaiting an urgent transplant. Given the breadth of therapeutic options available, specialised centres capable of delivering comprehensive care have become indispensable for optimising patient outcomes. These centres are instrumental in providing holistic support and management tailored to the complex needs of PH patients, ultimately enhancing their chances of a successful transplant and improved long-term prognosis.
引用
- Savale L, Benazzo A, Corris P, et al. Transplantation, bridging, and support technologies in pulmonary hypertension. Eur Respir J. 2024. PMID: 39209471. doi:10.1183/13993003.01193-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。